UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy

Supportive care in cancer, 2016-09, Vol.24 (9), p.3687-3693

2016

Volltextzugriff (PDF)

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

European journal of cancer (1990), 2021-05, Vol.149, p.153-164

2021

Volltextzugriff (PDF)

Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study

Annals of oncology, 2024-09

2024

Volltextzugriff (PDF)

Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis

Annals of oncology, 2020-12, Vol.31 (12), p.1775-1778

2020

Volltextzugriff (PDF)

Use of low-level laser therapy (LLLT) or photobiomodulation (PBM) for the management of the hand-foot syndrome (HSF) or palmo-plantar erythrodysesthesia (PPED) associated with cancer therapy

Supportive care in cancer, 2020-07, Vol.28 (7), p.3287-3290

2020

Volltextzugriff (PDF)

Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients

Journal of endocrinological investigation, 2016-07, Vol.39 (7), p.729-738

2016

Volltextzugriff (PDF)

1047P Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis

Annals of oncology, 2024-09, Vol.35, p.S699-S700

2024

Volltextzugriff (PDF)

Use of low-level laser therapy associated with cancer therapy

Supportive care in cancer, 2020-07, Vol.28 (7), p.3287

2020

Volltextzugriff (PDF)

Infection disséminée à Herpes simplex après talimogene laherparepvec (T-VEC) pour un carcinome épidermoïde chez un transplanté cardiaque

Annales de Dermatologie et de Vénéréologie - FMC, 2022-11, Vol.2 (8), p.A167

2022

Volltextzugriff (PDF)

Tamoxifen induced thromboembolic events in breast cancer. Some possible mechanisms

Revue médicale de Bruxelles, 2017, Vol.38 (6), p.494

2017

Volltextzugriff (PDF)

Progressive multifocal leukoencephalopathy, a possible complication in a patient with bladder cancer

Clinical case reports and reviews, 2015, Vol.1 (10)

2015

Volltextzugriff (PDF)

Tamoxifen induced thromboembolic events in breast cancer. Some possible mechanisms

Revue medicale de Bruxelles, 2017, Vol.38 (6), p.494-500

2017

Volltextzugriff (PDF)

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Nature reviews. Clinical oncology, 2019-09, Vol.16 (9), p.563-580

2019

Volltextzugriff (PDF)

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

Nature communications, 2024-04, Vol.15 (1), p.3664-3664, Article 3664

2024

Volltextzugriff (PDF)

Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15079-e15079

2020

Volltextzugriff (PDF)

Targeting immune checkpoints in breast cancer: an update of early results

ESMO open, 2017, Vol.2 (5), p.e000255-e000255, Article e000255

2017

Volltextzugriff (PDF)

Interactive process mining of cancer treatment sequences with melanoma real-world data

Frontiers in oncology, 2023-03, Vol.13, p.1043683-1043683

2023

Volltextzugriff (PDF)

Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.12129-12129

2024

Volltextzugriff (PDF)

Melanoma neoantigen vaccines: Are we getting more personal now?

Med (New York, N.Y. : Online), 2024-04, Vol.5 (4), p.288-290

2024

Volltextzugriff (PDF)

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events

Journal for immunotherapy of cancer, 2022-10, Vol.10 (10), p.e005635

2022

Volltextzugriff (PDF)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Journal for immunotherapy of cancer, 2021-02, Vol.9 (2), p.e001701

2021

Volltextzugriff (PDF)

Physical approaches to treat glioblastoma

Current opinion in oncology, 2020-11, Vol.32 (6), p.640-649

2020

Volltextzugriff (PDF)

Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series

Journal of neurology, 2024-04, Vol.271 (4), p.1947-1958

2024

Volltextzugriff (PDF)

Mucosal Melanoma of the Head and Neck: A Retrospective Review and Current Opinion

Frontiers in surgery, 2021-01, Vol.7, p.616174-616174

2021

Volltextzugriff (PDF)

Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy

CPT: pharmacometrics and systems pharmacology, 2023-08, Vol.12 (8), p.1170-1181

2023

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(53)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study

Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis

Use of low-level laser therapy (LLLT) or photobiomodulation (PBM) for the management of the hand-foot syndrome (HSF) or palmo-plantar erythrodysesthesia (PPED) associated with cancer therapy

Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients

1047P Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis

Use of low-level laser therapy associated with cancer therapy

Infection disséminée à Herpes simplex après talimogene laherparepvec (T-VEC) pour un carcinome épidermoïde chez un transplanté cardiaque

Tamoxifen induced thromboembolic events in breast cancer. Some possible mechanisms

Progressive multifocal leukoencephalopathy, a possible complication in a patient with bladder cancer

Tamoxifen induced thromboembolic events in breast cancer. Some possible mechanisms

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH)

Targeting immune checkpoints in breast cancer: an update of early results

Interactive process mining of cancer treatment sequences with melanoma real-world data

Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy

Melanoma neoantigen vaccines: Are we getting more personal now?

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Physical approaches to treat glioblastoma

Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series

Mucosal Melanoma of the Head and Neck: A Retrospective Review and Current Opinion

Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy

Suchergebnisse filtern